Procurement of CERLIPONASE 150MG IN 5ML

GoodsAward procedure without prior publication of a call for competition

Awarded value£650,000published contract · exc. VAT

Awarded 14 Dec 2022no call for competition

Awarded to Sciensus Pharma Services Ltd

Notice summaryFrom the published notice

CERLIPONASE 150MG IN 5ML - Continuity of Care.

What is being bought

Published requirement description

CERLIPONASE 150MG IN 5ML - Continuity of Care

CPV: Medical equipments, pharmaceuticals and personal care products

single lot · no lot value published

Lot #1Awarded

Delivery: Northern Ireland

Published awards, contracts and bid statistics, not a forecast

Awards 1

Awarded value £650,0001 contract exc. VAT

Bids received 1

Contracts signed 1latest 14 Dec 2022

Awarded to	Value	Date	Status
Sciensus Pharma Services Ltd	£650,000 †	—	Awarded

Contracts

Procurement of CERLIPONASE 150MG IN 5ML · Sciensus Pharma Services Ltd
Signed
14 Dec 2022
Value
£650,000
Status
active

Bid statistics published by the authority

Bids	SME	VCSE	Valid bid range
1bids	—	—	—

From the official record

Procedure method: Award procedure without prior publication of a call for competition
Legal basis: CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
Procurement category: Goods
Notice status: Awarded without competition
Procurement threshold: Unspecified in notice
Regulatory regime: Standard
Commercial structure: Stand-alone contract (no framework)
Competition type: Direct award (no call for competition)
GPA / WTO covered: Yes (GPA)
Recurring procurement: Unspecified in notice
First published: 20 Dec 2022, 12:38 GMT
Last source update: 20 Dec 2022, 12:38 GMT
Authority reference: DACPM2022-64
FTS notice number: 2022/S 000-036021
Classification (CPV): Medical equipments, pharmaceuticals and personal care products
Delivery area: Northern Ireland (UKN)
Official registry OCID: ocds-h6vhtk-0392d8 Find a Tender

Why no open competition: Additional deliveries by the original supplier ordered under the strict conditions stated in the directive
Published justification: These essential medicines are required for continuity of patient care. These medicines are available only from one economic operator. BHSCT can confirm that the absence of competition is not a result of the artificial narrowing of the parameters of the procurement.

Contracting authorityNHS & healthcareBody governed by public lawHealth LISBURN ROAD, BELFAST, Northern Ireland, BT97ABContact name, email

1 commercial party on the notice

Sciensus Pharma Services Ltd (HAH),Awarded supplierGB-COH: 02759609 107 Station Street, Burton-On-Trent, West Midlands, DE14 1SZ

Official links; attachments are not copied

No document links were published on the notice.